Hot Pursuit     18-Jun-24
Cipla hits record high as UK arm plans to invest additional 3 mln euro in Ethris
The pharma major announced that its wholly-owned subsidiary in United Kingdom, Cipla (EU) will invest an additional EUR 3 million in Ethris GmbH, a global leader in delivering mRNAs directly to the respiratory system.

This additional investment through a convertible loan will accelerate Cipla’s participation in the messenger RiboNucleic Acid (mRNA) space.

Earlier, Cipla had invested EUR 15 million in Ethris in 2022. This additional investment reaffirms Cipla’s confidence in Ethris’s proprietary mRNA platform and its potential for patients in emerging markets.

Together, Cipla and Ethris are working towards a long-term strategic partnership to fast-track innovative mRNA-based treatments, said the firm.

During the COVID19 pandemic, mRNA vaccines gained importance due to the first regulatory approvals for SARS-CoV-2. mRNA-based medicines have a huge potential in several indications as infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.

Umang Vohra, managing director (MD) & global chief executive officer (CEO), Cipla, said, “At Cipla, we strive to dial-up our focus and investment towards innovative modalities and bring new age therapies to emerging countries, including India. The follow-on investment in Ethris will help get cutting-edge healthcare solutions like mRNA-based therapies to the Global South.

Dr. Carsten Rudolph, CEO, Ethris, added, “The additional investment by Cipla further validates the broad potential of our platform and Ethris’ innovative approaches to developing respiratory RNA-based medicines. We deeply value this ongoing relationship to bring effective solutions to developing countries. The capital will enable us to continue advancing our pipeline and we look forward to providing an update on our lead program in the near term.”

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.

The pharma company reported 79% jump in consolidated net profit to Rs 939.04 crore on 10% increase in revenue from operations to Rs 6,163 core in Q4 FY24 over Q4 FY23.

The scrip hit an all time high of Rs 1,576.45 in today’s intraday session.

Previous News
  Cipla to conduct board meeting
 ( Corporate News - 02-Jul-25   10:19 )
  Cipla allots 43,396 equity shares under ESOP
 ( Corporate News - 27-Jun-25   11:02 )
  Cipla Ltd spurts 0.42%, up for fifth straight session
 ( Hot Pursuit - 11-Jun-25   13:00 )
  Cipla announced incorporation of subsidiary - CiplaRna GmbH' in Germany
 ( Corporate News - 29-May-25   18:50 )
  Jay Precision Pharmaceuticals acquires 26% stake in AMPIN Energy C&I Eighteen
 ( Corporate News - 29-May-25   18:48 )
  Cipla
 ( Results - Analysis 14-May-25   10:22 )
  Cipla to convene AGM
 ( Corporate News - 14-May-25   15:08 )
  Cipla registers PAT of Rs 1,222 crore in Q4; EBITDA margin rises to 22.8%
 ( Hot Pursuit - 13-May-25   15:17 )
  Board of Cipla recommends final dividend
 ( Corporate News - 13-May-25   14:34 )
  Board of Cipla recommends special dividend
 ( Corporate News - 13-May-25   14:34 )
  Cipla consolidated net profit rises 30.12% in the March 2025 quarter
 ( Results - Announcements 13-May-25   14:14 )
Other Stories
  Rajshree Polypack bags Rs 3-cr supply order
  05-Jul-25   16:04
  Power and Instrumentation secures Rs 3-cr work order from Nyati Engineering & Construction
  05-Jul-25   15:06
  RVNL bags Rs 143 cr LoA from Southern Railway for traction system upgrade in Tamil Nadu
  05-Jul-25   13:27
  Dhanlaxmi Bank gross advances rises 17% YoY in Q1 FY26
  05-Jul-25   12:45
  Texmaco Rail secures Rs 36-cr wagon order from TCI
  05-Jul-25   12:12
  Hazoor Multi Projects bags Rs 913-cr solar order from Apollo Green Energy
  05-Jul-25   11:27
  BEML secures $6.23 million export orders
  05-Jul-25   11:04
  Shakti Pumps raises Rs 292.6 crore via QIP; PineBridge, LIC MF among top investors
  05-Jul-25   09:52
  Bank of Maharashtra’s total deposits climb 14% YoY to Rs 3.05 lakh crore in Q1
  04-Jul-25   17:35
  GPT Infraprojects bags supply contract from Bangladesh-based Standard Engineers
  04-Jul-25   16:01
Back Top